Market Cap ₹ 15048Cr.
Current Price ₹ 24.5
Lot Size 500
52W High ₹ 78
Face Value 1
Debt to Equity 0.37
Stock P/E -3.8
Book Value ₹ 11.4
52W Low ₹ 23.54
Demat Account Both
|FY20||FY21||FY22||YOY % FY22||CAGR % FY22|
API Holdings is India’s largest digital healthcare platform with FY21 GMV of USD1.05bn. B2C operations added 21% to FY21 GMV while 72% was B2B. API serves as a wholesaler of pharma and OTC products using Retailio 1P (30% of GMV), as distributor using Retailio 3P (35%) and as medical supplier to hospitals/clinics using Aknamed (8%). Other major services for the company are diagnostics (Thyrocare), ERP systems (Redbook & Marg ERP), EMR & Teleconsult (Docon).
API Holdings Limited is India’s largest digital healthcare firm based on FY21 GMV of USD1.05bn. The company provides services like teleconsultation, diagnostics, B2B and B2C sale of pharma products, EMR systems. API is the parent entity of various healthcare platforms like Retailio, Redbook, Aknamed and Thyrocare.
API is the brand owner of Pharmeasy, marketplace run by Axelia: API holding’s wholly owned subsidiary Threpsi Solutions is the owner of the Pharmeasy brand. Threpsi Solutions has licensed the brand Pharmeasy to Axelia that operates the Pharmeasy marketplace. Axelia is 100% owned by Aarman Solutions and API holding has 19.99% stake in Aarman Solutions. The marketplace is the largest epharmacy platform in India by GMV and had a registered userbase of 25m as of Jun-21. In FY21/1QFY22, 8.8m/4.4m orders were transacted on the platform by 2.4m/2.1m unique customers resulting in GMV of INR10.6bn/5.2bn. As of Jun-21, 58% customers on the platform were from Tier II, III cities.
API Holding's B2B ops account for more than 2/3rd of total GMV: In FY21, 35% of API’s GMV came from Retailio 3P (third party), a digital platform used by pharmacies to order medicines. Retailio 1P (first party) accounted for 30% of GMV where API serves like a wholesaler; procures a wide range of pharma & OTC products directly from manufacturers and delivers them to retailers. As of Jun-21, 3,261 wholesalers (~5% of all domestic pharma wholesalers) used Retailio to transact with 87,194 pharmacies (11% of all pharmacies in India). On the digital platform, Retailio 1P is listed as one of the wholesalers. API also acts as a medical supplier to hospitals, doctors, clinics and medical centres. The business was scaled-up by the acquisition of Aknamed in Sep-21 which serviced 926 hospitals in 1QFY22. Currently, Retailio 3P earns revenue through advertisements on the platform.
API acquired Thyrocare in Sep-21 and has now become the largest diagnostic test provider by volume in the country. Thyrocare had a comprehensive portfolio of 283 diagnostics tests and 17 labs in India. API provides Electronic Medical Record (EMR), practice management software and teleconsult tools to doctors through its proprietary and AI driven predictive software called Docon (teleconsultation also available on mobile app Docon). During Jun-21, 4,617 prescribing doctors used Docon software and the teleconsultation tool.
India's HealthTech play is now getting integrated and most players are trying to provide various healthcare services under one roof. Though discounts remain important for attracting customers, equally important is the customer convenience, quality of service due to the innate nature of healthcare industry.
Mission & Vision:
The ultimate goal of PharmEasy is to provide affordable healthcare to one and all.
Various products and services span across the healthcare value chain and are currently at different stages of growth, market penetration, customer adoption, product development, and monetisation.
PharmEasy has acquired various healthcare companies to provide better service at affordable costs:
Key Strength of PharmEasy:
With these capabilities of their scaled presence, they now touch stakeholders across healthcare – consumers, pharmaceutical companies, wholesalers, pharmacies, hospitals, doctors and clinics and diagnostic and radiology labs. This presence allows them to offer integrated bouquet of products, services and technology to all stakeholders, with each having an ability to cross-sell services and products of one stakeholder to the other or their customers. As an illustration, pharmacies which are using the Retailio platform for their procurement and payments, can use Marg ERP Limited’s systems for their technology backbone, become a seller on the PharmEasy marketplace, offer tele-consult services by tying up with Docon and use the extensive Thyrocare network to provide diagnostic services.
This unique flywheel provides multiple stakeholders an opportunity to offer holistic healthcare solutions to the consumers, beyond their core service or product offering. Further, these solutions can be offered in a manner which is agnostic to the manner with which the consumers access the stakeholders, whether online or offline, and irrespective of where they would like to avail such services at their home or at point of sale.
They work closely with, and build technology-enabled services for consumers, pharmaceutical companies, wholesalers, pharmacies, hospitals, doctors and clinics and diagnostic and radiology labs. Their growing nationwide presence, the connected ecosystem approach, and multiple synergistic offerings have enabled them to build relationships with various stakeholders of the healthcare value chain. PharmEasy is India’s leading consumer healthcare super app for consumers (providing online pharmacy, OTC, teleconsultation and diagnostics services) in terms of GMV of products and services sold on the platform in the financial year 2021 according to the RedSeer Report.
Promoters and ShareHolding Pattern:
Source: Company Filing Form AOC-4
Source: Company Filing Form AOC-4
Source: Company Filing Form AOC-4
The company's revenue has grown massively increasing from INR 737.4 Cr in FY'20 to INR 2360.6 Cr in FY'21. This increase is mainly attributable to the massive rise in demand for pharmaceuticals due to the spread the of pandemic across the country. The assets of the company have shown a massive growth of 757% in FY'21 over FY'20. This growth in assets is attributable to the increase in cash and cash equivalents which have increased mainly due to the increase in deposit accounts by INR150.0 Cr in FY'21. The major reason of increase in assets is the growth in the goodwill value which has increased from INR 0.7 Cr in FY'20 to INR 3192.1 Cr in FY'21, which is because of the acquisition of Ascent Health as well as Medlife International including its subsidiaries in FY'21.
The cash flow from operations has further decreased by INR 361.6 Cr in FY'21 over FY'20. This is due to the large loss faced by the company in FY'21 as well as the increase in current liabilities which is mainly attributable to the large increase in the company's short term borrowings in FY'21.
Yes trading in unlisted shares is undoubtedly legal in India. The trading takes place in the over-the-counter market through various platforms like Stocx.in.
No, SEBI does not regulate the unlisted share market but certain rules and regulations of SEBI are applicable in the unlisted market space as well, such as, the DP charges for each transaction, stamp duty, lock-in period and more.
You will get the best price for API Holdings Ltd and a hassle-free buying experience only on Stocx.in platform.
API Holdings Ltd's unlisted shares can be easily purchased at Stocx.in by following a few easy steps. Given below are the steps involved in the buying of these shares:
Step 1 - Confirmation on the number of shares you want to purchase of API Holdings Ltd at a trading price.
Step 2 - Submission of the necessary document like your Client Master Report. Certain additional documents will also be asked for by our representative if required such as a cancelled cheque and your PAN Card if you are paying from a secondary bank account which is not mentioned in your CMR.
Step 3 - The Stocx.in representative will share the account details so that you can transfer the trade amount into the account.
Step 4 - The shares of API Holdings Ltd will reflect in your Demat account within 24 hours as soon as the payment is received and depending on the holidays. Our details would be available to you before the transfer.
API Holdings Ltd's unlisted shares can be easily sold at Stocx.in by following a few easy steps. Given below are the steps involved in the of selling of these shares:
Step 1- Confirmation on the number of shares you want to sell of API Holdings Ltd and at what price you want to sell.
Step 2- At Stocx, we will find a suitable buyer for you according to your requirements and if you accept the trade we will move on to the transfer and the payment aspect of the trade.
Step 3- The Stocx representative will provide you with the Demat account details to transfer your API Holdings Ltd shares. They will also notify you about the additional details required from your end before the transfer of shares such as client master copy, delivery instruction slip, and more.
Step 4- Once the transfer is complete, the payment would be credited to your bank account within 24 hours, depending on the holidays.
Over the years the minimum ticket size for investment has dropped as more and more people have started investing in the Unlisted market. Currently, the minimum ticket size for API Holdings Ltd is between 30K to 50K.
Brokers or dealers provide you with a trading facility means you can buy and sell shares with your broker but when you buy shares the Depository holds your shares. There are mainly two depositories NSDL and CDSL.
If you want to check your shares in NSDL and CDSL you need to download the application (NSDL Speede App or CDSL myeasi).
The taxation on the API Holdings Ltd shares may vary depending on 2 Factors:
Unlisted shares - In unlisted shares, the taxation of short-term capital gain i.e. less than 24 months is taxable according to the investor's income tax slab.
Listed Shares - In listed shares, the taxation for short-term capital gains i.e. less than 12 months is at 15%
Unlisted shares - The taxation for long-term capital gain i.e. more than 24 months is taxable at 20% with indexation benefits.
Listed Shares - The taxation for long-term capital gains i.e. more than 12 months is at 10% after an exemption of 1 lakh. There are no indexation benefits in listed shares.
According to the current rule issued by SEBI last year in August 2021, the lock-in period is brought down from 1 year to 6 months. This was done to entice more investors to invest their money in pre-IPO companies and startups. The lock-in period of API Holdings Ltd varies depending on which type of investor you are:
You can check daily share prices of companies on our website or register with us using your phone number where you will get daily whatsapp updates on company news and other essential informations.
Sell or Purchase Share (Tentative Price)